Comparison of Effects of Hemoglobin Levels Upon Tumor Response among Cervical Carcinoma Patients Undergoing Accelerated Hyperfractionated Radiotherapy versus Cisplatin Chemoradiotherapy

  • Thakur, Priyanka (Department of Radiotherapy, Regional Cancer Centre, Indira Gandhi Medical College) ;
  • Seam, Rajeev Kumar (Department of Radiotherapy, Regional Cancer Centre, Indira Gandhi Medical College) ;
  • Gupta, Manoj Kumar (Department of Radiotherapy, Regional Cancer Centre, Indira Gandhi Medical College) ;
  • Rastogi, Madhup (Department of Radiotherapy, Regional Cancer Centre, Indira Gandhi Medical College) ;
  • Gupta, Manish (Department of Radiotherapy, Regional Cancer Centre, Indira Gandhi Medical College) ;
  • Bhattacharyya, Tapesh (Department of Radiotherapy, Regional Cancer Centre, Indira Gandhi Medical College) ;
  • Sharma, Mukesh (Department of Radiotherapy, Regional Cancer Centre, Indira Gandhi Medical College) ;
  • Revannasiddaiah, Swaroop (Department of Radiotherapy, Regional Cancer Centre, Indira Gandhi Medical College)
  • Published : 2015.06.03


Purpose: Blood hemoglobin levels are known to influence response to radiotherapy. This retrospective analysis compared the effect of hemoglobin levels upon response to radiation among patients treated with radiation alone (by accelerated hyperfractionated radiotherapy) versus those treated with concurrent cisplatin chemoradiotherapy. Materials and Methods: Among patients treated for locally advanced carcinoma of the cervix (LACC) during 2009-10, a total of 60 fulfilled the eligibility criteria. In this time frame, external beam radiotherapy was delivered with either concurrent chemoradiotherapy (CRT, n=31) (45Gy over 25 fractions, with weekly cisplatin at 40mg/m2), or with accelerated hyperfractionated radiotherapy (AHRT, n=29) (20Gy over 10 daily fractions over the first two weeks, followed by 30Gy over 20 fractions over the next two weeks, with two fractions of 1.5Gy per day, without the use of chemotherapy). Mean weekly hemoglobin (MWH) levels of all patients were calculated as the arithmetic means of weekly recorded blood hemoglobin levels. As per MWH, patients in both of the AHRT or the CRT groups were classified into two subgroups-those with MWH between 10-10.9g/dL, or with MWH>11g/dL. Complete response (CR) to external beam RT phase (prior to brachytherapy) was declared after clinical examinations and computed tomography. The CR rate was noted for both MWH sub-groups within each of the AHRT and CRT groups. Results: Within the AHRT group, patients with MWH>11g/dL had a much better CR rate in comparison to those with MWH:10-10.9g/dL (80% vs. 21.1%) which was statistically significant (p 0.0045). Within the CRT group, there was no significant difference in the outcomes within the MWH>11g/dL and MWH:10-10.9g/dL sub-groups (CR rates of 80% vs. 61.9%, p=0.4285). Conclusions: The importance of maintaining a minimum hemoglobin level of 11g/dL during RT is much greater for patients treated with RT alone, than for patients treated with concurrent chemoradiotherapy. Enhanced haemoglobin levels during RT may to an extent negate the ill-effects that may otherwise arise due to non-use of concurrent chemotherapy.


  1. Chiara S, Bruzzone M, Merlini L, et al (1994). Randomized study comparing chemotherapy plus radiotherapy versus radiotherapy alone in FIGO stage IIB-III cervical carcinoma. GONO (North-West Oncologic Cooperative Group). Am J Clin Oncol, 17, 294-7.
  2. Das D, Chaudhuri S, Deb AR, et al (2011). Treatment of cervical carcinoma with high-dose rate intracavitary brachytherapy: two years follow-up study. Asian Pac J Cancer Prev, 12, 807-10.
  3. Dellas K, Bache M, Pigorsch SU, et al (2008). Prognostic impact of HIF-1alpha expression in patients with definitive radiotherapy for cervical cancer. Strahlenther Onkol, 184, 169-74.
  4. Dunst J, Kuhnt T, Strauss HG, et al (2003). Anemia in cervical cancers: impact on survival, patterns of relapse, and association with hypoxia and angiogenesis. Int J Radiat Oncol Biol Phys, 56, 778-87.
  5. Ferlay J, Shin HR, Bray F, et al (2010). Cancer incidence and mortality worldwide. GLOBOCAN 2008: IARC cancer Base No.10 [Internet]. Lyon, France: International agency for research on cancer. Available from: http://globocon.iarc. fr. Accessed on Jan 10, 2012.
  6. Green J, Kirwan J, Tierney J, et al (2005). Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev, 3, 2225.
  7. Grogan M, Thomas GM, Melamed I, et al (1999). The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer, 86, 1528-36.<1528::AID-CNCR20>3.0.CO;2-E
  8. Hall EJ, Giaccia AJ. Editors: Radiobiology for the radiologist, Lippincott Williams & Wilkins, 6th Ed., 2006.
  9. Kapp KS, Poschauko J, Geyer E, et al (2002). Evaluation of the effect of routine packed red blood cell transfusion in anemic cervix cancer patients treated with radical radiotherapy. Int J Radiat Oncol Biol Phys, 54, 58-66.
  10. Marchal C, Rangeard L, Brunaud C (2005). Anemia impact on treatments of cervical carcinomas. Cancer Radiother, 9, 87-95.
  11. National Cancer Registry Programme (2006). An overview. Indian Council Med Res, New Delhi.
  12. Negi RR, Gupta M, Kumar M, et al (2010). Concurrent chemoradiation in locally advanced carcinoma cervix patients. J Cancer Res Ther, 6, 159-66.
  13. Pearcey R, Brundage M, Drouin P, et al (2002). Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol, 20, 966-72.
  14. Resbeut M, Fondrinier E, Fervers B, et al (2003) .Standards, Options and Recommendations for the management of invasive cervical cancer patients (non metastastic). Bull Cancer, 90, 333-46.
  15. Saha A, Chaudhury AN, Bhowmik P, Chatterjee R (2010). Awareness of cervical cancer among female students of premier colleges in Kolkata, India. Asian Pac J Cancer Prev, 11, 1085-90.
  16. Sathian B, Fazil A, Sreedharan J, et al (2013). Statistical modelling and forecasting of cervix cancer cases in radiation oncology treatment: a hospital based study from Western Nepal. Asian Pac J Cancer Prev, 14, 2097-100.
  17. Shanta V (2003). Perspectives in cervical cancer prevention in India, . The international network for cancer treatment and research.
  18. Srivastava K, Paul S, Chufal KS, et al (2013). Concurrent chemoradiation versus radiotherapy alone in cervical carcinoma: A randomized phase III trial. Asia Pac J Clin Oncol, 9, 349-56.
  19. Thomas G, Dembo A, Ackerman I, et al (1998). A randomized trial of standard versus partially hyperfractionated radiation with or without concurrent 5-fluorouracil in locally advanced cervical cancer. Gynecol Oncol, 69, 137-45.
  20. Vaupel P, Kelleher DK, Hockel M (2001). Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol, 28, 29-35.
  21. Vaupel P, Thews O, Mayer A, Höckel S, Hockel M (2002). Oxygenation status of gynecologic tumors: what is the optimal hemoglobin level? Strahlenther Onkol, 178, 727-31.
  22. Vaupel P, Mayer A, Hockel M (2006). Impact of hemoglobin levels on tumor oxygenation: the higher, the better? Strahlenther Onkol, 182, 63-71.
  23. Vigario G, Kurohara SS, George FW (1973). Association of hemoglobin levels before and during radiotherapy with prognosis in uterine cervix cancer. Radiology, 106, 649-52.
  24. Wang N, Guan QL, Wang K, et al (2011). Radiochemotherapy versus radiotherapy in locally advanced cervical cancer: a meta-analysis. Arch Gynecol Obstet, 283, 103-8.